Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis

Joint Bone Spine

Volumn 79, Issue 1, 2012, Pages 100-101

  Ghrénassia, Etienne ^a   Mékinian, Arsène ^a   Rouaghe, Samir ^b   Ganne, Nathalie ^a   Fain, Olivier ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b Clinique des Courses   (France)

Author keywords

Resolved hepatitis B; Rheumatoid arthritis; Rituximab; Viral reactivation

Indexed keywords

ENTECAVIR; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; CASE REPORT; CHRONIC HEPATITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; PATIENT MONITORING; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; MALE; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84855690103     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.07.003     Document Type: Letter

References (10)

1. Kohrt H.E., Ouyang D.L., Keeffe E.B. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006, 24:1003-1016.
2. European Association for the Study of the Liver EASL clinical practice guidelines. Management of chronic hepatitis B. Gastroenterol Clin Biol 2009, 33:539-554.
3. Matsue K., Kimura S., Takanashi Y., et al. Reactivation of hepatitis B virus after Rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010, 116:4769-4776.
4. Yeo W., Chan T.C., Leung N.W., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without Rituximab. J Clin Oncol 2009, 27:605-611.
5. Hui C.K., Cheung W.W., Zhang H.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
6. Niitsu N., Hagiwara Y., Tanae K., et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010, 28:5097-5100.
7. Ji D., Cao J., Hong X., et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010, 85:243-250.
8. Pei S.N., Chen C.H., Lee C.M., et al. Reactivation of hepatitis B virus following Rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010, 89:255-262.
9. Fukushima N., Tanaka M., Yokoo M., et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009, 20:2013-2017.
10. Sarrecchia C., Cappelli A., Aiello P. HBV reactivation with fatal fulminating hepatitis during Rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005, 11:189-191.